318 related articles for article (PubMed ID: 30730576)
61. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
62. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies.
Spaggiari D; Geiser L; Daali Y; Rudaz S
J Pharm Biomed Anal; 2014 Dec; 101():221-37. PubMed ID: 24746851
[TBL] [Abstract][Full Text] [Related]
63. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities.
Dixit V; Hariparsad N; Desai P; Unadkat JD
Biopharm Drug Dispos; 2007 Jul; 28(5):257-62. PubMed ID: 17443647
[TBL] [Abstract][Full Text] [Related]
64. Rapid and accurate liquid chromatography and tandem mass spectrometry method for the simultaneous quantification of ten metabolic reactions catalyzed by hepatic cytochrome P450 enzymes.
Shi R; Ma B; Wu J; Wang T; Ma Y
J Sep Sci; 2015 Oct; 38(19):3363-73. PubMed ID: 26256777
[TBL] [Abstract][Full Text] [Related]
65. Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations.
Floby E; Briem S; Terelius Y; Sohlenius-Sternbeck AK
Xenobiotica; 2004; 34(11-12):949-59. PubMed ID: 15801540
[TBL] [Abstract][Full Text] [Related]
66. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
67. In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography-tandem mass spectrometry.
Seo KA; Kim HJ; Jeong ES; Abdalla N; Choi CS; Kim DH; Shin JG
Drug Metab Dispos; 2014 Nov; 42(11):1803-10. PubMed ID: 25122565
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach.
Chen A; Zhou X; Tang S; Liu M; Wang X
Sci Rep; 2016 Jun; 6():28482. PubMed ID: 27329697
[TBL] [Abstract][Full Text] [Related]
69. Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.
Li X; Chen X; Li Q; Wang L; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):128-37. PubMed ID: 17267297
[TBL] [Abstract][Full Text] [Related]
70. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography.
Lin T; Pan K; Mordenti J; Pan L
J Pharm Sci; 2007 Sep; 96(9):2485-93. PubMed ID: 17542019
[TBL] [Abstract][Full Text] [Related]
71. In vitro inhibition of human cytochrome P450 by cudratricusxanthone A.
Sim J; Choi E; Lee YM; Jeong GS; Lee S
Food Chem Toxicol; 2015 Jul; 81():171-175. PubMed ID: 25936586
[TBL] [Abstract][Full Text] [Related]
72. Study of in vitro metabolism of m-nisoldipine in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography-mass spectrometry.
Yuan L; Jia P; Sun Y; Zhao C; Zhi X; Sheng N; Zhang L
J Pharm Biomed Anal; 2014 Aug; 97():65-71. PubMed ID: 24816159
[TBL] [Abstract][Full Text] [Related]
73. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column.
Petsalo A; Turpeinen M; Pelkonen O; Tolonen A
J Chromatogr A; 2008 Dec; 1215(1-2):107-15. PubMed ID: 19019380
[TBL] [Abstract][Full Text] [Related]
74. Validated liquid chromatography-tandem mass spectrometry method for determination of totally nine probe metabolites of cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Lee JT; Pao LH; Hsiong CH; Huang PW; Shih TY; Yoa-Pu Hu O
Talanta; 2013 Mar; 106():220-8. PubMed ID: 23598120
[TBL] [Abstract][Full Text] [Related]
75. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.
Krishnan S; Moncrief S
Drug Metab Dispos; 2007 Jan; 35(1):180-4. PubMed ID: 17035599
[TBL] [Abstract][Full Text] [Related]
76. [The in vitro inhibition and induction of cytochrome P450 activities by bentysrepinine: a novel candidate of anti-hepatitis B virus drug].
Fan HR; Ci XY; Li W; Dong SQ; Zeng Y; Yi XL; Si DY; Liu CX
Yao Xue Xue Bao; 2016 Dec; 51(12):1864-70. PubMed ID: 29908557
[TBL] [Abstract][Full Text] [Related]
77. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
78. Development and validation of a sensitive and specific LC-MS/MS cocktail assay for CYP450 enzymes: Application to study the effect of catechin on rat hepatic CYP activity.
Nguyen V; Espiritu M; Elbarbry F
Biomed Chromatogr; 2020 Mar; 34(3):e4789. PubMed ID: 31885091
[TBL] [Abstract][Full Text] [Related]
79. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
80. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids.
He F; Bi HC; Xie ZY; Zuo Z; Li JK; Li X; Zhao LZ; Chen X; Huang M
Rapid Commun Mass Spectrom; 2007; 21(5):635-43. PubMed ID: 17279482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
